Cheaper eye drug proves as good as pricier one

Apr 28, 2011 By MARILYNN MARCHIONE , AP Medical Writer

A new study shows that a cheaper drug for a common eye disease is as effective as a more expensive one approved for the condition.

The study found that vision improvement was the same among patients given monthly shots of Avastin (ah-VAS-tin) or Lucentis (loo-SEN-tis) for one year. The patients have an disease called wet macular degeneration - a common cause of blindness in the elderly.

Avastin is a cancer that many doctors have used to treat the eye disorder even though it wasn't approved for that use. It costs about $50 per treatment compared to $2,000 for Lucentis. Both drugs are sold by Roche's Genentech unit.

Results were published online Thursday by the and will be presented at a meeting on Sunday.

Explore further: FDA approves second vaccine against meningitis strain

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Can further studies lower the cost of preserving vision?

Oct 04, 2006

The results of two large, randomized clinical trials published October 5, 2006, in the New England Journal of Medicine demonstrate that the drug ranibizumab is an effective treatment for neovascular macular degeneration, a comp ...

FDA says breast cancer drug did not extend lives

Jul 16, 2010

(AP) -- Federal health scientists said Friday that follow-up studies of a Roche breast cancer drug show it failed to slow tumor growth or extend patient lives, opening the door for a potential withdrawal in that indication.

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.